Earnings Release • Apr 25, 2024
Earnings Release
Open in ViewerOpens in native device viewer


VISIOMED GROUP (FR0013481835 - ALVMG), a group dedicated to innovative healthcare technologies and services, presents its audited financial results for the year 20231 , approved on 24 April 2024 by the Board of Directors.
"For the first time in its history, the company is presenting positive audited consolidated financial statements, with EBITDA reaching €2.2m in 2023, an increase of €4.3m compared with 2022, and a positive net income of €0.9m, an increase of €6.2m compared with 2022. The turnaround, which has been perceptible for several months, is now complete." said Clément Pacaud, CEO of Visiomed Group.
"As detailed in our last Letter to Shareholders, Visiomed Group is now a growing, profitable company with a healthy financial structure. The Group has a promising outlook, highlighted by the recent written offer received early 2024 from a GCC institutional investor, which the parties decided not to proceed with, valuing our UAE activities over €100m. We keep exploring different options with local investors and we will be open to contemplate equity and/or commercial opportunities."
| at 12/31 - € million | 2023 consolidated audited |
2022 consolidated audited |
change 23/22 (k€) |
var 23/22 (%) |
|---|---|---|---|---|
| Smart Salem revenue | 13.7 | 9.9 | 3.8 | 38% |
| Revenue of discontinued operations | 0.0 | 4.5 | (4.5) | na |
| Total revenue | 13.7 | 14.4 | (0.7) | -5% |
| EBITDA | 2.2 | (2.1) | 4.3 | |
| Ebitda Margin | 16% | -15% | 0.8 | |
| Net income | 0,9 | (5.3) | 4.2 | |
| Net Margin | 7% | -37% |
1 The 2023 Annual Financial Report will be made available on Tuesday 30 April 2024 (after close of trading). The closing of the accounts did not reveal any material differences from the unaudited financial information published in the press release of 26 March 2024, with the exception of net profit, which finally came out at €0.9m, compared with an estimate of €(1.1)m after taking into account non-cash accounting entries of €2.0m relating to asset value adjustments.


As explained in our press release of 26 March 20242 , several key factors contributed to these historic results for 2023:
These results validate the company's turnaround and the success of the new strategy initiated since April 2022 by the new management team.
On 4 April 2024, Visiomed Group also announced a strong start to the first quarter of 20243 .
Founded in 2007, VISIOMED GROUP relies on a long experience in the health sector to invest in innovative health technologies and services in France and abroad.
***
The Group now has focused its activities on the Middle East since 2021 and the acquisition of Smart Salem, the first digital medical analysis centre accredited by the Dubai Health Authority (DHA) in the United Arab Emirates, 100% owned by Visiomed Group.
Visiomed is also accelerating its development in the region with the creation of Smart Health, a joint venture that will lead the deployment of the Group's innovative centres in Saudi Arabia.
Based in Paris, Visiomed Group is listed on Euronext Growth (ALVMG). For more information, visit www.visiomedgroup.com
| ALVMC |
|---|
| EURONEXT GROWTH |

Jérôme FABREGUETTES LEIB Fatou-Kiné N'DIAYE [email protected] [email protected] Phone: +33 1 53 67 36 78 Phone: +33 1 53 67 36 75
Investor Relations Financial Press Relations
© Visiomed Group SA 2024. The brands mentioned are the property of their respective authors. Reproduction prohibited, even partial, without prior authorization.
2 FY 2023 results - a historic financial year for Visiomed Group
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.